1-3 of 3
Sara Wiegmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years

Free
Steven W Pipe, John P Sheehan, Michiel Coppens, Hermann Eichler, Camila Linardi, Sara Wiegmann, Charles RM Hay, Toshko Lissitchkov
Journal: Blood
Blood (2021) 138 (Supplement 1): 3971.
https://doi.org/10.1182/blood-2021-148661
Published: 2021
Journal Articles

Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A

Free
Alexander Solms, Anita Shah, Sara Wiegmann, Maurice Ahsman, Erik Berntorp, Andreas Tiede, MD, Alfonso Iorio, MDPhD, Maria Elisa Mancuso, Tihomir Zhivkov, Toshko Lissitchkov
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-136586
Published: 2020
Journal Articles

First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A - BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII

Free
Steven W. Pipe, MD, Francesca Ferrante, MD, Muriel Reis, Sara Wiegmann, Claudia Lange, Manuela Braun, Lisa A Michaels
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-139803
Published: 2020